Sign inCreate account

Report workspace tools

NCT05823623UNKNOWNanonymous

A Phase II Single-arm Clinical Trial of Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer

Sponsor

Source record

The First Affiliated Hospital with Nanjing Medical University

Phase

Source record

PHASE2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate

Indication / condition

AI-normalized

Breast Cancer

Intervention

Source record

Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate

Source & freshness

Source record

NCT ID

NCT05823623

Original source

ClinicalTrials.gov

Source last updated

Sep 14, 2023

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05823623

Title

A Phase II Single-arm Clinical Trial of Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Status

UNKNOWN

Phase

PHASE2

Condition raw

Breast Cancer

Condition normalized

Breast Cancer

Modality raw

breast cancer

Modality normalized

monoclonal antibody

Target raw

Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate

Target normalized

Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate

Interventions

Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate

Public preview

Source record

A Phase II Single-arm Clinical Trial of Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer is a PHASE2 clinical asset sponsored by The First Affiliated Hospital with Nanjing Medical University in Breast Cancer. SEO and diligence focus: Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase II Single-arm Clinical Trial of Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05823623

Status

UNKNOWN

Phase

PHASE2

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Executive brief

Investment-Ready Snapshot

A Phase II Single-arm Clinical Trial of Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer is a PHASE2 clinical asset sponsored by The First Affiliated Hospital with Nanjing Medical University in Breast Cancer. SEO and diligence focus: Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 14, 2023
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05823623

Indication

Breast Cancer

Modality

monoclonal antibody

Target

Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate

Intervention

Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.